Does Earnings Surprise History Hold Any Clue? While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Omnicell would post a loss of $0.08 per share when it actually produced earnings of $0.03, delivering a surprise of +137.50%. Over the last four quarters, the ...

The renowned healthcare technology company has a market capitalization of $1.36 billion. Omnicell surpassed estimates in each of the trailing four quarters, delivering an average negative earnings surprise of 93.2%. Image Source: Zacks Investment Research Macro Concerns Put Pressure on the Bottom Line: Myriad Genetics has been grappling with escalated expenses for a while. Deteriorating international trade, global inflationary pressure leading to a tough situation Estimate Trend Some better-ranked stocks in ...

Omnicell (OMCL) has been gaining from the successful execution of its growth strategies. Yet, macroeconomic concerns continue to impede growth. The stock carries a Zacks Rank #3 (Hold) currently. Omnicell strategizes to offer differentiated, innovative solutions, expand into new markets and grow through strategic partnerships and acquisition of new technologies. The company successfully increased its installed base of Point of Care connected devices through market share gains in the past three years. In 202 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNI ...

Omnicell, Inc. (OMCL) reported first-quarter 2024 adjusted earnings per share (EPS) of 3 cents compared with 39 cents in the year-ago quarter. However, the metric beat the Zacks Consensus Estimate of a loss of 8 cents per share.Adjustments include one-time expenses like share-based compensations, the amortization of acquired intangibles, acquisition-related expenses, executive transition costs, severance-related expenses and others.GAAP loss was 34 cents per share in the quarter under review compared with 3 ...

Financial Data and Key Metrics Changes - The first quarter 2024 GAAP earnings per share was a loss of $0.34, compared to a loss of $0.32 in the prior quarter and a loss of $0.33 in the first quarter of 2023 [5][6] - Total GAAP revenues for the first quarter 2024 were $246 million, a decrease of $13 million from the prior quarter and a decrease of $45 million compared to the first quarter of 2023 [22][39] - Non-GAAP earnings per share for the first quarter 2024 were $0.03, down from $0.33 in the prior quarter and $0.39 in the same period last year [7][14] - Non-GAAP EBITDA for the first quarter was $11 million, a decrease of $13 million from the previous quarter and a decrease of $16 million year-over-year [7][14] Business Line Data and Key Metrics Changes - Service revenues were $113 million, an increase of 8% over the first quarter of 2023, driven by growth in technical services [23] - Non-GAAP gross margin for the first quarter was 39.8%, a decrease of 380 basis points from the prior quarter due to lower revenue volume leverage [14][24] - The customer base for Specialty Pharmacy Services exceeded 400 hospitals and clinics, with new locations opening in the second quarter [16] Market Data and Key Metrics Changes - Health system finances are beginning to stabilize, with operating margins approaching 5% due to accelerating outpatient revenues and lower contract labor spending [41] - The interest rate environment remains challenging, impacting customer budgetary constraints [42] Company Strategy and Development Direction - The company plans to exit one international product line that was not delivering sufficient returns, as part of a strategy to streamline operations and unlock shareholder value [40] - The XT Amplify program is a multi-year initiative aimed at expanding product offerings and addressing unmet needs in various healthcare settings [11][19] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding customer financial health, noting improvements in discussions with clients [86] - The company is maintaining its guidance for the second quarter 2024, despite some headwinds from customers [115] Other Important Information - The company expects second quarter 2024 revenues to be between $250 million and $260 million, with product revenues between $140 million and $145 million [8] - Non-GAAP free cash flow during the first quarter of 2024 was $38 million, reflecting strong cash collections and working capital management [27] Q&A Session Summary Question: Can you walk us through the XT Amplify mid-cycle upgrade? - Management highlighted that the XT Amplify is more than just a console upgrade, involving multiple products and services aimed at addressing existing problems in healthcare settings [11] Question: What is the status of the regulatory review of the IVX robots? - Management indicated that they are monitoring the situation closely but have not seen any impact on business thus far [91] Question: How many more years of life does the cabinet get after the upgrade? - Management noted that the upgrade is essential for accessing new software and hardware versions, which will enhance the overall solution [44] Question: Can you elaborate on the focus on outcomes-based solutions? - Management acknowledged the importance of connecting pharmacy activities to patient outcomes and financial impacts, indicating ongoing evaluation of these connections [97] Question: What are the trends in the 340B program? - Management stated that the 340B program is expected to remain flat year-over-year, but it continues to be a valuable product when combined with specialty pharmacy services [76]

May 2, 2024 This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"), including Q1-2024 non-GAAP gross margin, non-GAAP operating expense, nonGAAP EBITDA, and non-GAAP earnings per share, 2017 and Q1-2024 liquidity and 2017 and Q1-2024 net debt/EBITDA, guidance with respect to 2024 non-GAAP EBITDA and non-GAAP earnings per share. Reconciliations of the 2017 and Q1-2024 non-GAAP financial measures to the most directly comp ...

Omnicell (OMCL) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 137.50%. A quarter ago, it was expected that this Omnicell Inc. Would post earnings of $0.17 per share when it actually produced earnings of $0.33, delivering a surprise of 94.12%.Over the last four quarters, th ...

Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 Kathleen.Nemeth@Omnicell.com Omnicell Announces First Quarter 2024 Results Results exceed prior first quarter guidance across all metrics Total GAAP revenues of $246 million FORT WORTH, Texas -- May 2, 2024 -- Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, t ...

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, will present at the virtual KeyBanc Annual Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024 at 4:30 p.m. ET. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centri ...